行情

CBLI

CBLI

克利夫兰生物实验室
NASDAQ

实时行情|Nasdaq Last Sale

1.320
+0.227
+20.75%
盘后: 1.850 +0.53 +40.15% 19:58 01/24 EST
开盘
1.090
昨收
1.093
最高
1.350
最低
1.080
成交量
38.06万
成交额
--
52周最高
2.160
52周最低
0.5000
市值
1,491.37万
市盈率(TTM)
-6.2887
分时
5日
1月
3月
1年
5年

EPS

CBLI 新闻

  • 13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak
  • Benzinga.3天前
  • City Of Beijing Cancels Major Public Events Including Chinese New Year Temple Fairs Due To Coronavirus Outbreak
  • Reuters.3天前
  • British Health Minister Says Has Not Yet Seen New Coronavirus Cases In UK
  • Reuters.3天前
  • A History Of Coronavirus Outbreaks And The Stock Market
  • Benzinga.4天前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

CBLI 简况

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
展开

Webull提供Cleveland BioLabs, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。